1. Wolf-Maier et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289, 2363–2369 (2003).2. Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–1642. 3. Muntner Petal.ALLHAT Collaborative Research Group: Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64: 1012–1021, 2014pmid:25259745.4. Muntner Petal.ALLHAT Collaborative Research Group: Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64: 1012–1021, 2014pmid:25259745.5. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000; 36: 594–599.6. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002; 4: 393–404. Crossref.7. Nishizaka MK et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805–812.8. He FJ et al. Effect of longer-term modest salt reduction onblood pressure. The Cochrane Database of Systemic Reviews. 2004;(3): 9. Henningsen NC et al. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand.1980;207:245–251. 10. J. P. Garg et al. Resistant hypertension revisited: a comparison of two university-based cohorts; American Journal of Hypertension, vol. 18, no. 5, pp. 619–626, 2005. 11. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289:2560-2572. 10.1001/jama.289.19.2560. 12. Whelton PK et al.: 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2018, 138:426-483. 13. Chapman N et al.Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007,49:839-845. 14. Pickering TG et al.Recommendations of blood pressure measurement in humans and experimental animals. Part 1:blood pressure measurement in humans. A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. 15. Egan BM et al.Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2016;18:817–824. 16. Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.